Founded by gene therapy developers, Forge Biologics is dedicated to advancing the accessibility of life-changing therapies. Operating from its 200,000+ square foot cGMP facility known as The Hearth in Columbus, Ohio, Forge provides end-to-end support for gene therapy programmes. The company integrates its proprietary FUEL™ platform, which includes technologies such as HEK293 suspension Ignition Cells™ and the pEMBR™ 2.0 adenovirus helper plasmid, to enhance manufacturing efficiency and scalability.

As a subsidiary of the Ajinomoto Group, Forge benefits from the global scale and scientific innovation of its parent company, further strengthening its capabilities in gene therapy development and manufacturing.

Key Products and Services

• AAV Manufacturing: Forge offers research-grade production, process development, and cGMP manufacturing services for AAV vectors, supporting various stages from discovery through to commercial production.

• FUEL™ Platform: An innovative AAV manufacturing foundation that includes advanced technologies and product-specific optimisations to increase productivity and maintain product quality.

• Plasmid Production: In-house services for plasmid cell banking and manufacturing, supporting both research-grade and cGMP requirements.

• Process Development and Analytical Services: Tailored process development strategies and comprehensive analytical services to optimise yield, purity, and efficiency.

• Fill-Finish and Regulatory Support: Integrated services to support the final stages of manufacturing and ensure compliance with regulatory standards.

Forge Biologics has supported over 50 clients across more than 35 indications, manufacturing over 500 batches to date.The company's commitment to innovation and quality positions it as a trusted partner in the gene therapy sector.